Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Feb 12, 2024 12:41pm
221 Views
Post# 35875761

Regarding news flow?

Regarding news flow?

Oncolytics biotech news flow?
looking @ history, it is possibe the next N.R. Not due until a few weeks, when they will announce upcoming Q4 & year end results.That being first week of March.
That reporting is a legal requirement & looking back has been within +/- only a few days of previous years.
Could we continue with the radio silence until the yr end uplate?
With 6+ analysts covering, they typically update target's & recommendations after the quarterly updates.
Unlike the many of us, they are legally bound to base their recommendations & valuations on " something of substance"
Many can argue one way or the other around their reports. Bottom line they disclose where the predictions come from, with a plethora of disclaimers.
Understand all that, Onc needs a plan & needs to bring forward the details.
again....very soon.
This story has now IMHO come down to weeks not quarters or months.
The mangement team, B.O.D. & clinical advisory
committee , are all very educated with decades of biotech background. 

They know the score both technically & financially.
id love to be a fly in the wall in the board room's right now 

 

<< Previous
Bullboard Posts
Next >>